Thyroid Cancer and Nuclear Accidents (ePub)

Shunichi Yamashita graduated from Nagasaki University School of Medicine in March 1978 and spent almost three years from July 1984 to March 1987 as an endocrine research fellow at the Cedars-Sinai Medical Center. In 1990, Dr. Yamashita became a full Professor of Molecular Medicine and International Radiation Health at the Atomic Bomb Disease Institute, Nagasaki University School of Medicine. He has been deeply involved in Chernobyl and Semipalatinsk medical aid projects for more than 25 years. Professor Yamashita is the Adviser to the Governor of Fukushima Prefecture on Health Risk Management. He was dispatched from Nagasaki University to Fukushima since the Fukushima Nuclear Accident and assumed the position of Director of Radiation Medical Science Center for the Fukushima Health Management Survey. In April 2013 Professor Yamashita returned officially to Nagasaki University as the Trustee and Vice-President. Currently he serves as Senior Director of the FMU Radiation Medical Science Center. He was the former President of the Japan Thyroid Association and also a council member of the Asia & Oceania Thyroid Association, and Director of the WHO collaborating center for research on Radiation Emergency Medical Preparedness and Response Network. He is also the member of Science Council of Japan

Gerry Thomas is Professor of Molecular Pathology at Imperial College and is committed to developing infrastructures for research into molecular mechanisms of cancer. She strongly believes that public involvement and information is a key part of academic research, and is actively involved in the public communication of research, particularly with respect to radiation protection and biobanking. She has carried out research into the health effects of the Chernobyl accident since 1992, and established the Chernobyl Tissue Bank (CTB: www.chernobyltissuebank.com) in 1998. The CTB has provided infrastructural support (both physical and ethical) in Belarus, Ukraine and Russia for

Dieses eBook können Sie uneingeschränkt auf allen Geräten der tolino Familie lesen. Zum Lesen auf sonstigen eReadern und am PC benötigen Sie eine Adobe ID.